{"id":"W2170071316","doi":"10.1200/jco.2005.02.129","title":"Randomized Phase II Study of Two Doses of Gefitinib in Hormone-Refractory Prostate Cancer: A Trial of the National Cancer Institute of Canada-Clinical Trials Group","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":207,"is_retracted":false,"has_abstract":true,"ca_institutions":"Vancouver General Hospital; Princess Margaret Cancer Centre; Jewish General Hospital; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Gefitinib; Cancer; Rash; Chemotherapy; Prostate-specific antigen; Randomized controlled trial; Clinical trial; Oncology; Epidermal growth factor receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002922285,0.001895981,0.002567411,0.0005190711,0.0009154293,0.0009112204,0.00115752,0.002134096,0.006221148],"category_scores_gemma":[0.002054738,0.0006866261,0.00130858,0.0006291392,0.001494436,0.0006147001,0.0003618475,0.003037665,0.0007635236],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003530298,"about_ca_system_score_gemma":0.006902004,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0263855,"about_ca_topic_score_gemma":0.08273563,"domain_scores_codex":[0.9989084,0.0005456491,0.00004299899,0.0001703233,0.000134642,0.0001979627],"domain_scores_gemma":[0.9985231,0.0001945609,0.0003236624,0.00007875227,0.0001267102,0.000753403],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.969277,0.008077069,0.001443192,0.0004285129,0.0008040766,0.00005315126,0.00006288561,0.0005085224,0.002012746,0.0001585294,0.002286854,0.01488743],"study_design_scores_gemma":[0.9711962,0.0251347,0.002344257,0.00001413705,0.0001699046,0.00002241283,0.000009303892,0.0001971123,0.0001335808,0.00004767607,0.000721563,0.000009126922],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9650756,0.008529844,0.0008041901,0.002441857,0.0005826864,0.01531866,0.00314448,0.0001632895,0.00393926],"genre_scores_gemma":[0.964727,0.004152395,0.003113296,0.002799107,0.0004619003,0.01473909,0.003044337,0.00002848384,0.006934375],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0263855,"threshold_uncertainty_score":0.05246389,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3188633390056988,"score_gpt":0.5975672502723148,"score_spread":0.278703911266616,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}